These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 25362236)
1. Gynecologic oncologic imaging with PET/CT. Grant P; Sakellis C; Jacene HA Semin Nucl Med; 2014; 44(6):461-78. PubMed ID: 25362236 [TBL] [Abstract][Full Text] [Related]
2. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Metser U; Even-Sapir E Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153 [TBL] [Abstract][Full Text] [Related]
4. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409 [TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography in gynecologic cancer. Yen TC; Lai CH Semin Nucl Med; 2006 Jan; 36(1):93-104. PubMed ID: 16356798 [TBL] [Abstract][Full Text] [Related]
7. FDG PET-CT of gynecologic cancers: pearls and pitfalls. Prabhakar HB; Kraeft JJ; Schorge JO; Scott JA; Lee SI Abdom Imaging; 2015 Oct; 40(7):2472-85. PubMed ID: 25680500 [TBL] [Abstract][Full Text] [Related]
8. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. De Gaetano AM; Calcagni ML; Rufini V; Valentini AL; Gui B; Giordano A; Bonomo L Abdom Imaging; 2009 Nov; 34(6):696-711. PubMed ID: 18791682 [TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography-computed tomography imaging for malignancies in women. Viswanathan C; Bhosale PR; Shah SN; Vikram R Radiol Clin North Am; 2013 Nov; 51(6):1111-25. PubMed ID: 24210447 [TBL] [Abstract][Full Text] [Related]
10. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
11. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Thrall MM; DeLoia JA; Gallion H; Avril N Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284 [TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT in monitoring response to treatment in gynecological malignancies. Amit A; Person O; Keidar Z Curr Opin Obstet Gynecol; 2013 Feb; 25(1):17-22. PubMed ID: 23299090 [TBL] [Abstract][Full Text] [Related]
13. The Role of PET Imaging in Gynecologic Radiation Oncology. Rao YJ; Grigsby PW PET Clin; 2018 Apr; 13(2):225-237. PubMed ID: 29482751 [TBL] [Abstract][Full Text] [Related]
14. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509 [TBL] [Abstract][Full Text] [Related]
15. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905 [TBL] [Abstract][Full Text] [Related]